Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
+28.9%
Total debt
+140.8%

Quarter to September 2026, against a year earlier

110.08 3.52 −3.10%
Market cap
$196.6B
P/E
41.1×
Fwd P/E
35.1×
Dividend yield
2.29%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100

Abbott Laboratories 10-K filed Feb 21, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed · accepted 4:07 PM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors: no comparison — no earlier filing on file